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ABSTRACT 
______________________________________________________________ 
 
The development and growth of agricultural products as well as the food industrialization have 
led to dramatic lifestyle changes, particularly in dietary patterns, which in turn has lead to 
increased occurrence of chronic diseases (i.e. cardiovascular, stroke and hypertension). In order 
to overcome these side effects, the food industry has developed functional milks. Milk 
products, particularly fermented milk containing probiotics are most popular. The advantages 
of utilizing probiotics is for gut health, reduced allergenicity, increased bio-accessibility of 
fats/proteins in foods, and lowering of blood pressure due to poly-amines and bioactive 
peptides. In addition, bioactive peptides have been shown to lower the risk of hypertension and 
cancer. Herein, we discuss the potential role of fermented milk as functional milk against 
hypertension. However, longer term research studies are necessary to evaluate the role of 
fermented milk drinks to support human health. 
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1. Introduction 
 
 Nutrition concepts today are moving away from prevention to promotion of health and 
wellness, and due to increased education and awareness to consumers the link between diet and 
health has become a major focus. As such, this trend has created a demand for functional foods, 
or ‘foods that contain some health-promoting components beyond traditional nutrients’ [1]. 
The market for functional foods is large in the US, it was valued at US$21 billion (B) in 2006, 
with a 5 % annual growth till 2011 [2] and increased to 25 % and valued at US$43.27B in 2014 
[3]. However, following the economic crisis in recent years, the market for functional foods 
has suffered mainly owing due to consumers turning to cheaper food options as well as changes 
being implicated in food regulations. In addition, in the European Union manufacturers are 
being pressured to provide scientific evidence for the health benefit claims of functional foods 
[3].  
 Foods can be modified to become ‘functional’ either by hydrolysis by digestive 
gastrointestinal enzymes or during food processing [4]. This effectively releases bioactive 
peptides from an inactive state in the protein molecule [4]. The role of bioactive peptides in 
promoting wellness has been attributed to their physiological and physiochemical benefits such 
as, anti-thrombotic, anti-hypertensive, anti-microbial, anti-oxidative and immunomodulatory 
[5]. To attain anti-hypertensive function, angiotensin converting enzyme inhibitory (ACE-I) 
peptides are required to be absorbed by the intestine in an active form prior to reaching the 
targeted organ. One of the challenges with oral ingestion however is their stability. As such, 
they need to survive degradation by gastrointestinal proteinases and peptidases before being 
absorbed into the system [5]. In fact, recent efforts have focused on transdermal delivery of 
anti-hypertensive peptides and drugs in order to bypass gastrointestinal degradation [6]. 
 Bovine milk typically is composed of water (87.1 %), lactose (4.6 %), milk proteins 
(3.3 %) and fat (4 %) [7]. There are 2 types of milk proteins, 80 % casein and 20 % whey 
protein (WP) and are characterized based on their solubility at pH 4.6; casein is insoluble 
whereas WP is soluble [8]. WP is a mixture of bovine serum albumin (8 %), α-lactalbumin (25 
%), β-lactoglobulin (65 %) and other minor constituents such as, immunoglobulins, protease 
peptones, lacto peroxidase, lysosome and lactoferrin [9]. WP usually comes in powder form 
either as whey protein concentrate (WPC; 85 % protein, low fat and cholesterol levels, high 
levels of bioactive compounds) or whey protein isolate (WPI; >90 % protein and low levels of 
fat, cholesterol and bioactive compounds) and is marketed as a dietary supplement with wide 
4 
 
health claims [10]. In general, milk proteins are used as a source of bioactive peptides as they 
are considered economical and safe. The production of bioactive peptides from fermented milk 
products has been widely studied, and the effectiveness of bioactive peptides depend on its 
amino acid sequence [11, 12]. Herein, we present important studies on the anti-hypertensive 
properties of milk proteins in light of increasing scientific knowledge regarding ACE-I activity 
of these compounds. 
 
2. Methodology 
 
 This review article presents current knowledge of the probiotics in particular lactic acid 
bacteria (LAB) in the fermentation of milk proteins to result in functional milk products. The 
LAB and the fermentation process produces bioactive peptides which have numerous health 
benefits. PubMed/Medline and Google Scholar were searched for relevant articles using the 
following key terms: LAB OR Lactobacillus AND bioactive peptides (this resulted in 161 
papers), Streptococcus AND bioactive peptides (55 papers), Bifidobacterium AND bioactive 
peptides (24 papers), probiotics AND bioactive peptides (82 papers), probiotics AND health 
(5,794 papers, only screened titles from 2018 (451/5,794) and only chose those related to 
hypertension), probiotics AND hypertension (118 papers), sensory evaluation AND peptides 
AND milk (12 papers), whey/casein AND bioactive peptides (137 papers), bioactive peptides 
AND hypertension AND human AND milk (36 papers).  
 Publications in the last 10 years are mostly cited. Papers that were discarded are those 
that showed that probiotics resulted in bioactive peptides but were not relevant to anti-
hypertensive properties; enzymatic and chemical synthesis of bioactive peptides; dairy food 
preservation; fruits and vegetables as source of bioactive compounds; non-dairy products; anti-
bacterial properties of compounds; microorganisms and food contamination; heat shock 
proteins; bioactive peptides in functional meat products; gut microbiome; in silico 
characterization of bioactive peptides; conference abstracts and papers not in English were also 
excluded. 
 
3. Fermentation of dairy products  
 
 Fermentation of dairy products can be dated as far back as 10,000BC and the 
fermentation process requires the use gram positive, acid-tolerant bacteria Lactobacillales or 
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LAB which produce lactic acid as a main end product of fermentation. LAB include, 
Lactobacillus, Streptococcus and Bifidobacterium ssp. and, are commonly referred to as 
probiotics (Table 1). Probiotics are defined as ‘live microorganisms that when administered in 
adequate amounts confer health benefits to the host’ [13, 14]. The genera of microorganisms, 
yeast and enzymes that are commonly used to release bioactive peptides from milk proteins are 
listed in Table 1 [15, 16]. Fermentation improves shelf life, taste and digestibility of milk [17]. 
Fermentation knowledge is essential in driving research forward into their role in health and 
how they can be used to overcome disease, such as, autoimmunity, allergies, diabetes and 
cancers [18]. The ‘quality’ of fermented dairy products (potency, efficacy, stability and 
immunomodulatory abilities) is determined by the equipment and methods used. One such 
approach is the use of the bioreactor which results in high quality fermented products with high 
yields (Figure 1). There are different types of bioreactors used such as, stirred tank reactors, 
tower fermenters, airlift fermenters and hollow fibre chambers; for research, small-scale 
bioreactors are used [18]. Bioreactors can be used to monitor and controlling pH by acid/base 
addition or CO2/base addition, temperature regulation, sterile sampling capability and mixing 
such that the cultures remain in suspension. All this is achieved without damage to the micro-
organisms. As such, the bioreactor process has been developed for dairy fermentation products 
including the production of yoghurt, cheese, butter milk, Kefir (Table 2) [19]. Although 
yoghurt containing Lactobacillus acidophilus or Bifidobacterium ssp. would generally be 
classified as ‘fermented milk’ [20], according to the Australian food standards code, the pH of 
yoghurt should be < 4.5 and therefore is prepared with S. thermophilus and L. delbrueckii ssp., 
bulgaricus or other LAB [21]. The fermentation processes results in changes in the structure 
of milk proteins, leading to the production of some amino acids and peptides from milk proteins 
with bioactive properties [17, 22-24].  
 
4. Production of bioactive peptides 
 
 The protein content in food is a source of peptides, which when cleaved intact become 
active. Bioactive peptides are effective in promoting human health by decreasing the risk of 
chronic diseases, such as hypertension [25]. Bioactive peptides are produced during 
gastrointestinal enzymatic degradation of proteins or during food processing such as 
fermentation [26, 27]. In addition, bioactive peptides can be produced by heat, alkaline or 
acidic conditions, enzymes and microbial fermentation of proteins [27]. Enzymatic hydrolysis 
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using trypsin, papain or subtilisin is used to produce low molecular weight bioactive peptides; 
subtilisin being more potent than papain and trypsin [28]. Likewise, subtilisin hydrolysis of 
rice bran proteins was more efficient in producing low molecular weight bioactive peptides 
than papain and pepsin [29]. In addition, ACE-I peptides are most commonly produced by 
trypsin. However, other enzymes and enzyme combinations of alkalase, pepsin, pancreatin and 
enzymes from bacterial and fungal sources, have been used to produce bioactive peptides [24].  
 Microbial fermentation involves the culture of some bacteria or yeast with proteins; 
bacteria and yeast secrete enzymes which break down proteins into bioactive peptides. The 
extent of hydrolysis is dependent on the strain used, type of protein and the time of 
fermentation. LAB such as Lactobacillus helveticus is usually used in milk processing to 
produce cheese. The release of amino acids by action of peptidases is an essential part of the 
LAB proteolytic system. Tri-peptides, IPP and VPP are generated from sour milk fermented 
with Lactobacillus helveticus CP790 and Saccharomyces cerevisiae (Ahtesh et al., 2018 
submitted). Several studies have reported over ten peptides as part of Lactobacillus helveticus 
proteolytic system; (PepE, PepO, PepT, PepX, PepI, PepQ, PepR, PepD, PepV, PepC, PepN) 
[30, 31]. Another study identified seven oligo endo peptidases and eight di- and tri- peptidases 
in Lactobacillus helveticus strain CNRZ32 [32].  
 
5. Functional food products 
 
5.1. Health benefits of fermented milk products 
 
 The process of fermentation increases the concentration of enzymes and vitamin B, C, 
D and K content. LAB (Lactobacillus, Streptococcus or Bifidobacterium) are used to ferment 
milk products (i.e. yoghurt, buttermilk, kefir) which have been shown to confer health benefits 
beyond their nutritional qualities (Table 1, 2, Figure 1). The efficacy of some probiotics against 
diarrhoea has been reported [33], as well as providing intestinal microbial balance [34], reduces 
the risk of colon and breast cancer [35], reduces blood pressure [17, 22-24, 36], reduces lipid 
profiles [37], reduces allergies and food intolerances [38], inhibits the growth of pathogenic 
bacteria and is immunomodulatory [12, 39-42] (Figure 1). More recently, dysbiosis has been 
implicated to be involved in the pathogenesis of a number of disorders such as, Sjogren’s 
syndrome [43], Parkinson’s disease [44] and multiple sclerosis [45]. The use of probiotics and 
prebiotics could be used as therapeutic approaches against diseases. In fact, it was recently 
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reported that consumption of probiotics had an overall positive relationship with lactose 
intolerance [46]. In order to determine the mechanism by which fermented milk consumption 
confers health benefits, serum metabolome was measured in 14 healthy males in a randomized 
crossover study following consumption of either non-fermented milk or yoghurt. It was noted 
that the yoghurt group had higher concentrations of 7 free amino acids, reduction of 5 bile acids 
and modulation of 4 indole derivatives compared to the non-fermented group suggesting novel 
health benefits of fermented milk products [47]. Fermented milk treatment in, in vitro semi-
continuous anaerobic cultivation of the colon showed that butyrate producing bacteria were 
altered as well as some metabolites, including butyrate, ethanol and lactate [48]. In addition, 
Lactobacillus plantarum YW11 decreases nitric oxide, increases the content of short chain 
fatty acids, shows anti-oxidant activity and regulates microbiota activities in the intestine 
bringing new insights into the mechanisms conferred by probiotics [49]. Furthermore, in mice, 
consumption of probiotic yoghurt increased subcuticular folliculogenesis resulting in thick 
shiny fur [50]. Moreover, probiotics regulate cellular and humoral immune responses as well 
as inducing regulatory T cells and anti-inflammatory cytokines [39-42], beneficial for a number 
of inflammatory disorders. It is clear that fermented milk products confer an array of health 
benefits however, further randomized controlled studies are required to elucidate such benefits. 
 
5.2. Regulation of blood pressure     
 
 Blood pressure is one of the leading risk factors for cardiovascular disease and this risk 
increases progressively above 120/80 mmHg. Hypertension is related to increase systolic and 
diastolic blood pressure and is defined as being above 140/90 mmHg. According to the 
Australian health survey 2011-2012, one third of the world’s adult population were 
hypertensive in the year 2011-2012. Of these people > 75 % were overweight/obese and 42 % 
reporting to doing no exercise. Hypertension usually co-morbids with other risk factors, such 
as, metabolic syndrome, insulin resistance and high cholesterol levels (and chronic 
inflammation) [51-53]. High blood pressure in the short term affects the sympathetic nervous 
system whereas in the long term body fluid volume and the function of the kidneys are greatly 
affected [53, 54]. A key system that regulates body fluids and blood pressure is the hormone 
system, the renin-angiotensin system (RAS) (Figure 1) [55, 56]. Renin is secreted by the kidney 
when renal blood flow is low which converts angiotensinogen secreted by the liver into 
angiotensin I (AT1) which is then converted to ATII by the enzyme, angiotensin-converting 
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enzyme (ACE) found in the lungs. ATII (a strong vasoconstrictor) stimulates the hormone 
aldosterone from the adrenal cortex and as a result increases blood pressure and water retention. 
The importance of the RAS in hypertension have been shown by the clinical benefits of ACE 
inhibitors (ACE-I), AT1 and ATII receptor blockers (ARBs) as well as renin inhibitors [57, 
58]. Using molecular modelling, components of the RAS (especially ACE-I peptides) have 
been designed and used as anti-hypertensives [59]. More recently, alamandine, a vasoactive 
peptide of the RAS, was shown to reverse vascular dysfunction via the protein kinase A 
pathway [60]. Examples of ACE-I include benazepril hydrochloride, captopril, perindopril, 
enalapril maleate and of ARBs include candesartan, irbesartan, losartan, valsartan. Although 
ACE-I are used to treat hypertension, heart failure patients, to prevent kidney disease and 
improve survival following heart attacks and, ARBs are used to prevent diabetes and recurrence 
of atrial fibrillation, there are many side effects associated with these [61]. ACE-I side effects 
include, cough, skin rash, change in taste, angiodema, increased uric acid, elevated potassium 
levels, liver dysfunction, allergic reactions, low blood cell counts, pancreatitis and kidney 
failure. ARBs may cause dizziness, diarrhea, rash, orthostatic hypotension, indigestion, lung 
infections, kidney and liver failure, allergic reactions, decreased platelets and angioedema [61]. 
Due to the adverse effects of long term use of ACE-I and ARBs, much research has focused 
on the production of bioactive peptides from fermented milk products. Peptides are known for 
their high tissue affinities and thus, may be more slowly eliminated from tissues compared to 
synthetic drugs. 
 
5.3. Anti-hypertensive bioactive peptides  
 
Milk derived bioactive peptides with anti-hypertensive attributes are highly studied and a 
number of reviews regarding their production, bioavailability and inclusion into foods are 
published [26, 27].  Fermentation of WP with Lactobacillus brevis has higher ACE-I activity 
than whey protein fermented with Lactobacillus -acidophilus, -casei, -helveticus, -lactis or -
reuteri. Thus, different microorganisms have different proteolytic systems and different ACE-
I activities [62]. In addition, studies report the ability to hydrolyse α–lactalbumin, β-
lactoglobulin and immunoglobulins from WPs in order to produce bioactive peptides [63].  
 
5.3.1. In vitro ACE-I activity: In vitro, several peptides of varying amino acid lengths have 
been shown to inhibit ACE at M concentrations [64]. Inhibition of ACE activity reduces the 
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production of ANGII leading to lowered blood pressure. In addition, the bradykinin system 
involves ACE which causes blood vessels to dilate, consequently reducing blood pressure 
(Figure 1) [64, 65]. It is plausible that small molecular weight ACE-I peptides would move 
through the gut epithelium and into circulation to reach target sites and reduce blood pressure. 
As such, fermentation of milk proteins have been utilized to produce bioactive peptides with 
ACE-I activities. Bioactive peptides with ACE-I activities are aimed to block the conversion 
of ANGI to ANGII or inhibiting the degradation of bradykinin. In fact, Lactobacillus helveticus 
fermented whey protein produced the peptides AHKAL, APLRV, AQSAP and IPAVF with 
strong ACE-I. However, whey fermented with Lactobacillus brevis produced a different 
peptide AEKTK, but also with ACE-I activity [62]. Additionaly, using Lactobacills casei and 
kombucha cultures resulted in 21 new peptides (6-18 amino acids in length) of which 
LVESPPELNTVQ, VLESPPELN, WGYLAYGLD were confirmed to have ACE-I activity 
[66].  
 
5.3.2. Anti-hypertensive activity in animal models: The WP fraction of yoghurt fermented 
with Lactobacillus helveticus has been found to contain the dipeptide YP with anti-
hypertensive effects in spontaneous hypertensive rats (Figure 1) [67]. Furthermore, the peptides 
DPYKLRP and DY produced from lactoferrin and bamboo shoots respectively following 
fermentation with Kluyveromyces marxianus have ACE-I activity and reduce blood pressure 
in spontaneous hypertensive rats. The peptides FFVAPFPEVFGK, FFVAP and AVPYPQR 
derived from casein potentiate bradykinin in the contraction of the ileum of rats reducing blood 
pressure [68]. The renin inhibitory peptide IRLIIVLMPILMA hydrolyzed from red seaweed 
Palmaria palmata using the enzyme papain also reduces systolic blood pressure in spontaneous 
hypertensive rats [69]. Likewise, RVPSL peptide isolated from hen egg protein has been shown 
to be an ARB and has potential to be used in the treatment or prevention of hypertension [70].  
  
5.3.3. Clinical studies: In humans, the peptides VPP and IPP released from casein following 
culture with Lactobacillus helveticus CP790 and Saccharomyces cerevisiae have been shown 
to reduce blood pressure [71]. These peptides were shown to be absorbed directly by the 
epithelium without being hydrolyzed by digestive enzymes reaching the target sites for anti-
hypertensive effects [72, 73]. In a 12 weeks double-blind parallel intervention study of 89 
hypertensive subjects who consumed either VPP/IPP peptides in milk compared to placebo 
milk significantly reduced arterial stiffness (augmentation index) [74]. An addition, 94 
hypertensive patients in a randomized double blinded placebo-controlled study who consumed 
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Lactobacillus helveticus fermented milk (with a high concentration of VPP/IPP peptides), 
twice a day for 10 weeks, lowered blood pressure compared to control product [75]. In a longer 
study over 21 weeks similar anti-hypertensive effects were noted [76]. Likewise, in 
hypertensive humans, who consumed fermented milk or a spread containing the ACE-I 
peptides, VPP and IPP, daily for 10-12 weeks showed reduced blood pressure [77]. IPP and 
VPP interact with subsides S1, S1' and S2' at the active site of ACE; thus ACE prefers 
hydrophobic amino acid residues in the three C-terminal positions. As a consequence of the 
anti-hypertensive abilities of the bioactive peptides, several fermented milk products have been 
developed and are consumed for the management of hypertension (Figure 1), although, the 
European food and safety authority has not approved such approach to be used alone as a 
treatment and management of hypertension. Further human intervention studies are therefore 
crucial to establish the anti-hypertensive and health benefits of milk derived bioactive peptides. 
 
6. Sensory evaluation of milk products  
 
 Evaluation of the sensory characteristics is defined as a scientific judgment of food 
quality using senses, such as smell, taste, touch and sight [17]. It is divided into 2 categories, 
(i) objective testing which uses laboratory equipment with no involvement of senses and (ii) 
subjective testing involving a group of panellists which includes the senses (sight, smell, taste, 
flavor, touch, sound). Both objective and subjective tests are required in sensory evaluation 
[17]. As such the Hendonic scale is commonly used by panellists to evaluate liking of food 
products, such as, a bioactive milk product. After food production and before reaching the 
marketplace, new food products go through many tests to accurately judge how well people 
will accept them [17, 78]. Manufacturing companies are required to evaluate the new product 
by particular food gastronomy and respond to the following: (i) will people like the product? 
(ii) will they buy the product? what price? (iii) how can the product be successfully marketed 
to people? and (iv) will they prefer the product over others? Useful information can be obtained 
by posing specific questions to panels about age, sex, religion, geographic nationality, location, 
employment and education.  Lastly, marketing and quality control are additional applications 
of sensory testing [78]. Sensory evaluation is a valuable tool, especially for commercial 
companies, as the outcomes are fast, practical and simple [79]. 
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7. Conclusion  
 
 Several species of probiotics strains are potential contributors to the regulation of high 
blood pressure, lipid metabolism, diabetes and are immunomodulatory, due to the effectiveness 
of the bioactive peptides produced during fermentation. We described anti-hypertensive 
peptides released from fermented milk products eventhough there are still a large number of 
peptides released from milk protien hydrolysis still to be evaluated. There is a need to determine 
the mechanisms of bioactive peptides and their metabolites and their gene changes on cells 
using RNAsequencing in order to better understand the mechanistic effects of peptides at the 
molecular level. This information will aid in the development of more effective therapeutic 
strategies and achieve better outcomes.  
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Table 1 
The genera of microorganisms, yeast and enzymes that are commonly used to release bioactive 
peptides from milk proteins. 
___________________________________________________________________________ 
Microorganisms   Yeast    Enzymes and others 
___________________________________________________________________________ 
L. acidophilus    Candida krusei  Alcalase® 
L. casei    Galactomyces geotrichum Bacillus cereus 
L. delbrueckii ssp. Bulgaricus Geotrichum candidum Bacillus clausii 
L. farciminis    Kluyveromyces marxianus Bacillus oligonitrophilis 
L. gasseri    Pichia subpelliculosa   Clostridium butyricum 
L. helveticus    Saccharomyces boulardii Enterococcus faecium 
L. johnsonii    Saccharomyces cerevisiae Flavourzyme® 
L. paracasei     Saccharomyces kefir  Propionibacterium 
freudenreichii    Schizosaccharomyces pombe 
L. rhamnosus      
L. salivarius 
Lactococcus lactic ssp. cremoris 
Lactococcus lactis 
B. acolescentis 
B. animalis 
B. bifidum 
B. breve 
B. infantis 
B. lactis 
B. longum 
B. thermophilum 
___________________________________________________________________________ 
Bifidobacterium (B), Lactobacillus (L) 
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Table 2 
Fermented products, microorganisms used and health benefits 
___________________________________________________________________________ 
Dairy product  Milk used   Microorganism used 
___________________________________________________________________________ 
Yoghurt   Cow    S. thermophilus 
        L. bulgaricus, L. acidophilus 
Lassi    Buffalo, Cow   L. bulgaricus 
Kefir    Sheep, cow, goat  Saccharomyces, S. lactis, Kefir 
Cheese    Cow, goat, sheep, buffalo L. lactis, S. therpmophilus 
        L. delbueckii subsp. bulgaricus 
        Penicillum roqueforti, etc 
Curd    Cow, buffalo   L. lactis, S. thermophilus 
        L. delbueckii subsp. bulgaricus 
        S. cremoris 
Acidophilus milk  Cow    L. acidophilus 
Bulgarian butter milk  Cow    L. delbueckii subsp. bulgaricus 
___________________________________________________________________________ 
Fermented products  Constituents   Health benefits 
 
Kefir    Vitamin B12, K2, calcium Immunomodulator,  
(milk)    magnesium, biotin, folate improves - irritable bowel   
        syndrome, allergies, digestion  
        and kills candida 
 
Yoghurt   Vitamin B2, B12, calcium, Immunomodulator, improves  
(milk)    potassium, magnesium, cardiovascular system, increases  
    protein,   triglycerides 
 
Kombucha   Vitamin B, enzymes  Improves digestion, energy, 
(black tea and sugar)  acetic acid, lactic acid  prevents cancer, immunomodulator 
 
Pickles    Vitamin A, K2, fibre  Improves heart and bone health 
(i.e. cucumber)  anti-oxidants, calcium 
 
Sauerkraut   Vitamin A, B, C, K, iron Improves digestion, circulation,  
(cabbage)   manganese, magnesium,  reduces cholesterol and inflammation 
 
Tempeh   Vitamin B2, 3, 5, 6,  Reduces cholesterol, increases  
(soybean)   high protein   bone density, muscle recovery,  
        reduces menopausal symptoms 
 
Miso    Vitamin K2, omega-3, fibre, Anti-ageing, immunomodulatory, 
(barley, soybean or  zinc, protein,    reduces cancer risk, improves  
brown rice)       bone health and nervous system 
 
Natto    Vitamin K2, calcium  Immunomodulatory, improves  
(soybean)   enzyme nattokinase,  cardiovascular system, bone and  
        digestion, anti-cancer 
___________________________________________________________________________ 
Bifidobacterium (B), Lactobacillus (L), Streptococcus (S) 
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Figures 
 
Fig. 1. Schematic representation of the bioreactor to produce fermented dairy products from 
milk and lactic acid bacteria (LAB). Fermented dairy products have an array of health benefits 
including that against hypertension. In addition, milk proteins (whey and casein) when mixed 
with LAB at the appropriate pH and time, release bioactive peptides from protein which have 
angiotensin converting enzyme (ACE)-inhibitory activity, angiotensin receptor blocking 
(ARB) activity or bradykinin protective activity. 
 
 
 
 
 
